Literature DB >> 497518

Electrophysiological actions of mexiletine (Kö1173) on canine Purkinje fibres and ventricular muscle.

M Arita, M Goto, Y Nagamoto, T Saikawa.   

Abstract

1 The effects of mexiletine (Kö1173) were investigated in canine isolated cardiac Purkinje fibres and ventricular muscle with microelectrodes. Some Purkinje fibres were depolarized by mechanical stretch to induce spontaneous activity with slow upstroke velocity. The preparations were stimulated at rates of 1, 2, 3 and 4 Hz. The drug concentrations tested were 0.4, 2 and 10 mug/ml in Tyrode solution (KCl = 5.4 mM).2 The ;therapeutic' drug concentration (2 mug/ml) shortened action potential duration and effective refractory period of Purkinje fibres, the effect being pronounced at lower stimulation rates. In ventricular fibres, action potential duration changes were not consistent while the effective refractory period was prolonged.3 In depolarized Purkinje fibres showing automatic activity, the drug (0.4 or 2 mug/ml) depressed phase 4 depolarization and reduced the firing rate without changing maximum diastolic potential. However, when depolarized Purkinje fibres were electrically driven at a constant rate, the maximum diastolic potential became more negative with a concomitant decrease of pacemaker slope and increase of maximum rate of rise (V(max)) of action potentials.4 Moderate (2 mug/ml) to high (10 mug/ml) concentrations of the drug depressed V(max) in Purkinje fibres stimulated at 2 Hz by 12 and 42% respectively and depressed ;membrane responsiveness'. The decrease in V(max) depended upon the stimulation rate, being minimum at the lowest (1 Hz) and maximum at the highest (4 Hz) stimulation rate.5 The drug (2 mug/ml) improved V(max) of the earliest propagated premature action potentials by shifting the takeoff potential to more negative levels in both Purkinje and ventricular fibres.6 Membrane conductance in fibres mounted in a single sucrose gap chamber was increased by the drug (2 mug/ml) in both fibre types in normal and in Na(+)-deficient solutions. This increase was attributed to an increase in membrane K(+) permeability produced by the drug.7 All these effects are similar to those of lignocaine, diphenylhydantoin or aprindine, and can explain the antiarrhythmic action of mexiletine.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 497518      PMCID: PMC2043595     

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  IONIC CURRENTS IN CARDIAC EXCITATION.

Authors:  K A DECK; W TRAUTWEIN
Journal:  Pflugers Arch Gesamte Physiol Menschen Tiere       Date:  1964-06-09

2.  [CHANGES IN THE RESTING POTENTIAL AND THE CABLE PROPERTIES OF PURKINJE FIBERS DURING STRETCH].

Authors:  K A DECK
Journal:  Pflugers Arch Gesamte Physiol Menschen Tiere       Date:  1964-07-01

3.  Current-voltage relations of Purkinje fibres in sodium-deficient solutions.

Authors:  A E HALL; O F HUTTER; D NOBLE
Journal:  J Physiol       Date:  1963-04       Impact factor: 5.182

4.  The plateau of the action potential of the frog ventricle.

Authors:  W V MACFARLANE
Journal:  Circ Res       Date:  1960-01       Impact factor: 17.367

5.  Treatment of ventricular arrhythmias with mexiletine (Kö 1173).

Authors:  R G Talbot; J Nimmo; D G Julian; R A Clark; J M Neilson; L F Prescott
Journal:  Lancet       Date:  1973-08-25       Impact factor: 79.321

Review 6.  Ventricular fibrillation.

Authors:  B Surawicz
Journal:  Am J Cardiol       Date:  1971-09       Impact factor: 2.778

7.  Outward membrane currents activated in the plateau range of potentials in cardiac Purkinje fibres.

Authors:  D Noble; R W Tsien
Journal:  J Physiol       Date:  1969-01       Impact factor: 5.182

8.  Experimental studies on the antiarrhythmic action of a lidocaine analog.

Authors:  K Okuma; S Sugiyama; M Wada; J Sugenoya; N Niimi
Journal:  Cardiology       Date:  1976       Impact factor: 1.869

9.  Electrophysiological effects of mexiletine in man.

Authors:  J C Roos; A C Paalman; A J Dunning
Journal:  Br Heart J       Date:  1976-12

10.  Mexiletine (Kö 1173) in the management of ventricular dysrhythmias.

Authors:  N P Campbell; J G Kelly; R G Shanks; N C Chaturvedi; J E Strong; J F Pantridge
Journal:  Lancet       Date:  1973-08-25       Impact factor: 79.321

View more
  4 in total

1.  Concentration- and rate-dependent electrophysiological effects of restacorin on isolated canine Purkinje fibres.

Authors:  A Varrò; T K Knilans; P P Nànàsi; G Rabloczky; D A Lathrop
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-12       Impact factor: 3.000

2.  Effect of mexiletine, amiodarone and disopyramide on the excitability and refractoriness of canine cardiac fibers: possible relation to antiarrhythmic drug action and classification.

Authors:  Y Nakaya; V Elharrar; B Surawicz
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

3.  Mexiletine-induced shortening of the action potential duration of ventricular muscles by activation of ATP-sensitive K+ channels.

Authors:  T Sato; S Shigematsu; M Arita
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

4.  Comparative antidysrhythmic and haemodynamic effects of orally or intravenously administered mexiletine and ORG 6001 in the anaesthetized rat.

Authors:  R J Marshall; A W Muir; E Winslow
Journal:  Br J Pharmacol       Date:  1981-10       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.